Danaher Corporation (DHR)

Danaher (NYSE:DHR) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Healthcare stocks have lagged the broader stock market over the past year. Political tensions following the slaying of an insurance executive and policy uncertainty following the transition to the Tru...

Investors looking for stocks in the Medical Services sector might want to consider either Bausch + Lomb (BLCO) or Danaher (DHR). But which of these two stocks offers value investors a better bang for ...

Danaher is undervalued, with strong fundamentals, robust free cash flow, and a "Buy" rating targeting $210 (12.7% upside). DHR's bioprocessing segment drives growth, balancing Life Sciences weakness, ...

DHR's Diagnostics unit posts steady Q2 growth, led by Beckman Coulter demand, while China headwinds weigh on results.

DHR's Life Sciences unit faces revenue declines from weak demand, but new products and biotech advances offer growth potential.

DHR's Biotechnology unit grows 6% in Q2, driven by bioprocessing, despite weakness in research equipment demand.

DHR posts gains in bioprocessing, biotech and diagnostics, while life sciences softness and high debt weigh.

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...